KT502 for Rheumatoid Arthritis
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 27 (estimated)
- Sponsor
- Kali Therapeutics, Inc. · Industry
This trial is looking for adults between 18 and 75 years old with rheumatoid arthritis. Participants will receive KT502 injections to help researchers study its safety and how it works in the body.
You may be able to join if
- I am between 18 to 75 years old.
- I have been diagnosed with rheumatoid arthritis for at least 6 months.
- I have moderately to severely active rheumatoid arthritis.
- My rheumatoid arthritis treatment has not been effective.
- I have tested positive for rheumatoid factor or ACPA.
- I am currently stable on traditional RA medications.
- I am willing and able to follow the study rules and schedule.
You may not be able to join if
- I am classified as functional class IV for rheumatoid arthritis.
- I have another autoimmune disease besides rheumatoid arthritis.
- I currently have an active infection or a history of serious infections.
- I have a history of progressive multifocal leukoencephalopathy.
- I have had cancer in the last 5 years or breast cancer within the last 10 years.
- I have had or planned to have an organ transplant.
- I received a live vaccine within the last 4 weeks.
- I have had major surgery in the last 8 weeks or plan to have major surgery in the next 6 months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.
Loading trial locations…